middl
east
respiratori
syndrom
mer
coronaviru
merscov
emerg
infecti
coronaviru
first
report
human
saudi
arabia
bat
like
natur
reservoir
viru
dromedari
camel
import
intermedi
camel
import
mode
transport
particularli
middl
east
applic
anim
contribut
significantli
cameltocamel
cameltohuman
transmiss
merscov
addit
merscov
may
also
transmit
human
commun
hospit
set
sinc
first
emerg
merscov
continu
infect
human
high
mortal
rate
http
wwwwhointemergenciesmerscoven
situat
call
consist
effort
develop
effect
countermeasur
includ
therapeut
antibodi
vaccin
prevent
treat
merscov
infect
merscov
spike
protein
envelop
glycoprotein
play
key
role
viral
infect
viral
attach
viral
entri
compos
subunit
receptorbind
domain
rbd
subunit
mediat
merscov
bind
cellular
receptor
dipeptidyl
peptidas
subunit
subsequ
mediat
viral
cell
membran
fusion
lead
viral
entri
target
cell
rbd
merscov
protein
contain
critic
neutral
domain
fragment
capabl
induc
strong
neutral
antibodi
therefor
consid
import
therapeut
vaccin
target
sever
monoclon
antibodi
mab
develop
prevent
treat
merscov
infect
agent
base
rbd
howev
convent
igg
mab
antibodi
fragment
often
complex
structur
unstabl
behavior
consequ
antimerscov
therapeut
antibodi
strong
stabil
simplifi
structur
would
clinic
valuabl
camelid
heavi
chain
variabl
domain
vhh
also
term
nanobodi
nb
deriv
variabl
domain
camelid
heavi
chainonli
antibodi
hcab
antibodi
distinct
properti
includ
high
bind
affin
strong
specif
target
antigen
good
tissu
penetr
intrins
stabil
harsh
condit
extrem
ph
valu
proteas
chemic
high
temperatur
accordingli
repres
promis
therapeut
tool
treatment
human
diseas
moreov
nb
requir
pair
light
heavi
chain
domain
maintain
antigenbind
activ
easili
modifi
protein
engin
techniqu
without
loss
function
sever
monomer
nb
readili
fuse
form
multival
multispecif
construct
therebi
improv
bind
affin
function
exampl
monomer
protein
engin
dimer
trimer
protein
also
multidomain
nb
gener
link
differ
nb
target
influenza
viru
hemagglutinin
protein
result
agent
greater
breadth
avid
potenc
crossneutr
activ
diverg
influenza
virus
parent
molecul
demonstr
feasibl
engin
nb
target
multipl
epitop
increas
activ
therefor
worthwhil
attempt
gener
multidomain
nb
improv
activ
emerg
reemerg
infecti
virus
previous
immun
llama
recombin
merscov
rbd
protein
gener
monomer
nb
mononb
target
rbd
merscov
protein
studi
construct
two
oligomer
nb
includ
dimer
nb
dinb
trimer
nb
trinb
compar
mononb
term
abil
bind
rbd
protein
inhibit
receptor
bind
crossneutr
merscov
infect
addit
demonstr
advantag
oligomer
nb
rel
convent
antibodi
evalu
stabil
nb
extrem
condit
mention
overal
data
show
engin
oligomer
nb
significantli
improv
standpoint
bind
affin
rbd
inhibit
bind
crossneutr
activ
diverg
strain
merscov
also
maintain
greater
ph
proteas
chemic
thermal
stabil
mab
counterpart
dimer
trimer
nb
specif
merscov
rbd
construct
link
two
three
monomer
nb
mononb
gggg
linker
ctermin
tag
follow
insert
pichia
pastori
yeast
secretori
express
vector
invitrogen
carlsbad
ca
usa
recombin
nb
express
pichia
pastori
cell
purifi
use
ninta
column
ge
healthcar
cincinnati
oh
usa
merscov
rbdspecif
nb
detect
sdspage
western
blot
previous
describ
briefli
nb
resolv
trisglycin
sdspage
gel
follow
stain
coomassi
brilliant
blue
transfer
nitrocellulos
membran
membran
block
overnight
pbst
contain
nonfat
milk
incub
h
room
temperatur
goat
antillama
igg
antibodi
abcam
cambridg
usa
horseradish
peroxidas
hrp
conjug
antigoat
igg
antibodi
r
system
minneapoli
mn
usa
treat
membran
incub
ecl
western
blot
substrat
reagent
abcam
visual
use
amersham
hyperfilm
ge
healthcar
merscov
rbdspecif
mous
mab
mer
mab
sarscov
rbdspecif
mous
mab
sar
mab
includ
control
bind
nb
merscov
rbd
protein
detect
elisa
previous
describ
briefli
elisa
plate
coat
overnight
recombin
wildtyp
mutant
merscov
rbd
contain
ctermin
human
fc
tag
plate
block
pbst
h
sequenti
incub
serial
dilut
nb
goat
antillama
antibodi
abcam
hrpconjug
antigoat
igg
antibodi
abcam
h
wash
plate
incub
substrat
tetramethylbenzidin
sigma
st
loui
mo
usa
reaction
stop
n
absorb
nm
measur
elisa
micropl
reader
tecan
morrisvil
nc
usa
compar
bind
activ
median
effect
concentr
calcul
previous
describ
bind
nb
merscov
rbd
protein
detect
use
instrument
ge
healthcar
previous
describ
briefli
recombin
fcfuse
merscov
rbd
protein
captur
sensor
chip
protein
ge
healthcar
recombin
nb
variou
concentr
flow
chip
surfac
mm
hepe
ph
mm
nacl
mm
edta
surfact
buffer
sensorgram
analyz
use
biacor
softwar
ge
healthcar
bind
model
fit
data
inhibit
bind
merscov
rbd
cellsurfac
receptor
nb
analyz
flow
cytometri
previous
describ
briefli
cell
incub
room
temperatur
min
merscov
rbdfc
protein
without
serial
dilut
nb
cell
incub
min
fitclabel
antihuman
igg
antibodi
sigma
analyz
flow
cytometri
percentag
inhibit
calcul
base
fluoresc
intens
bind
presenc
vs
absenc
nb
neutral
activ
merscov
rbdspecif
nb
initi
measur
live
merscovbas
neutral
assay
previous
describ
briefli
merscov
strain
median
tissu
cultur
infect
dose
incub
nb
h
nbviru
mixtur
ad
vero
cell
cultur
h
cytopath
effect
cpe
observ
daili
neutral
activ
nb
report
neutral
dose
method
use
calcul
valu
nb
crossneutr
activ
merscov
rbdspecif
nb
measur
pseudotyp
merscov
neutral
assay
previous
describ
briefli
cell
cotransfect
plasmid
encod
envdefect
luciferaseexpress
genom
plasmid
encod
merscov
protein
pseudotyp
merscov
harvest
cultur
supernat
h
transfect
incub
serial
dilut
nb
h
ad
cell
h
cell
lyse
cell
lysi
buffer
promega
madison
wi
usa
incub
luciferas
substrat
promega
assay
rel
luciferas
activ
tecan
infinit
pro
lumin
tecan
nb
calcul
previous
describ
stabil
nb
respect
chang
ph
evalu
incub
pb
variou
ph
valu
h
room
temperatur
stabil
nb
presenc
chaotrop
denatur
evalu
incub
pb
contain
gradient
concentr
urea
sigma
h
stabil
nb
respect
proteolysi
evalu
incub
mm
hcl
buffer
ph
contain
variou
concentr
pepsin
sigma
h
thermal
stabil
nb
evalu
incub
pb
variou
temperatur
h
treat
nontreat
nb
subject
mer
pseudoviru
neutral
assay
mer
mab
sar
mab
includ
control
statist
analysi
perform
student
twotail
ttest
use
graphpad
prism
statist
softwar
san
diego
ca
usa
p
valu
lower
consid
statist
signific
indic
p
p
p
respect
hcab
present
camelid
shark
contain
heavi
chain
light
chain
antigenbind
fragment
camelid
hcab
also
call
vhh
figur
left
previous
use
pcr
amplifi
merscov
rbdspecif
vhh
gene
construct
mononb
target
merscov
rbd
link
construct
ctermin
tag
easi
purif
result
total
molecular
weight
kda
gener
dinb
trinb
specif
merscov
rbd
linearli
link
two
three
mononb
respect
flexibl
gggg
linker
mononb
ctermin
tag
figur
right
mononb
dinb
trinb
express
cultur
supernat
yeast
express
cell
high
yield
puriti
form
dimer
trimer
molecular
weight
kda
respect
figur
left
merscov
rbdtarget
nb
react
strongli
antillama
antibodi
figur
right
data
suggest
like
mononb
merscov
rbdspecif
dinb
trinb
maintain
nativ
conform
strong
antigen
determin
whether
engin
nb
stronger
bind
affin
merscov
rbd
protein
perform
elisa
test
bind
wildtyp
merscov
rbd
protein
fuse
ctermin
rbdwt
well
fcfuse
rbd
protein
contain
mutat
merscov
strain
isol
human
camel
result
reveal
rel
mononb
dinb
especi
trinb
bound
significantli
strongli
rbd
test
expect
bind
dosedepend
figur
addit
bind
affin
mer
mab
control
similar
mononb
wherea
bind
sar
mab
control
indistinguish
background
figur
perform
spr
assay
test
bind
affin
nb
rbdwt
result
reveal
mononb
dinb
trinb
antibodi
bind
affin
kd
valu
nm
pm
pm
respect
toward
rbdwt
figur
perform
microneutr
assay
investig
neutral
activ
engin
merscov
rbdspecif
nb
live
merscov
strain
infect
result
reveal
dinb
trinb
potent
neutral
merscov
infect
significantli
lower
mononb
figur
previous
demonstr
molecular
mechan
merscov
rbdspecif
mononb
suppress
merscov
involv
inhibit
receptor
bind
perform
elisa
flow
cytometri
assay
investig
whether
engin
dinb
trinb
could
inhibit
bind
greater
extent
mononb
elisa
result
reveal
dinb
trinb
block
bind
merscov
rbd
ie
rbdwt
strongli
mononb
inhibit
dosedepend
figur
flow
cytometri
assay
reveal
dinb
trinb
significantli
greater
abil
mononb
block
bind
rbd
ie
rbdwt
cellassoci
inhibit
dosedepend
figur
case
mer
mab
control
inhibit
bind
well
better
mononb
wherea
inhibit
sar
mab
control
indistinguish
background
figur
c
taken
togeth
data
describ
suggest
rel
monomer
nb
merscov
rbdspecif
dimer
trimer
nb
exhibit
significantli
improv
bind
affin
toward
merscov
rbd
protein
elev
neutral
activ
toward
merscov
infect
potent
inhibit
merscov
rbd
bind
receptor
nb
gener
intrins
stabil
varieti
extrem
condit
includ
low
high
ph
temperatur
exposur
proteas
pepsin
chaotrop
agent
urea
investig
stabil
merscov
rbdtarget
nb
subject
extrem
condit
test
neutral
activ
pseudotyp
merscov
express
protein
strain
shown
tabl
nb
includ
mononb
dinb
trinb
still
abl
neutral
pseudotyp
merscov
infect
treatment
three
differ
ph
valu
ph
variou
concentr
pepsin
urea
three
temperatur
sampl
maintain
neutral
activ
similar
respect
untreat
counterpart
although
mer
mab
control
treat
treat
three
ph
valu
maintain
similar
neutral
activ
pseudotyp
merscov
infect
significantli
lost
neutral
abil
incub
urea
pepsin
pretreat
expect
sar
mab
control
crossneutr
activ
merscov
treatment
data
indic
rel
tradit
mab
target
merscov
rbd
merscov
rbdspecif
nb
maintain
greater
stabil
extrem
condit
test
merscov
undergon
number
mutat
includ
rbd
henc
critic
merscov
rbdspecif
nb
maintain
potent
crossneutr
activ
merscov
diverg
strain
addit
pseudotyp
merscov
express
protein
prototyp
merscov
strain
construct
addit
pseudotyp
merscov
contain
rbd
mutat
merscov
isol
seven
countri
saudi
arabia
uk
qatar
oman
jordan
south
korea
uae
differ
time
period
two
host
human
camel
tabl
addit
test
neutral
activ
merscov
rbdspecif
nb
shown
tabl
rel
mononb
dinb
especi
trinb
significantli
elev
neutral
activ
virus
test
rang
nm
mononb
nm
dinb
nm
trinb
neutral
activ
mer
mab
much
lower
dinb
trinb
merscov
strain
test
sar
mab
neutral
activ
virus
data
indic
merscov
rbdspecif
oligomer
nb
exhibit
higher
level
crossneutr
activ
diverg
merscov
strain
merscov
continu
pose
sever
threat
public
health
worldwid
due
high
mortal
rate
steadi
increas
clinic
case
particularli
saudi
arabia
current
mer
vaccin
therapeut
approv
use
human
creat
urgent
demand
efficaci
vaccin
therapeut
agent
capabl
prevent
merscov
transmiss
infect
well
treat
merscovinfect
human
camel
term
antibodi
therapi
antibodi
high
product
good
antigenbind
affin
potent
neutral
activ
diverg
strain
merscov
infect
would
greatest
practic
use
unlik
convent
igg
antibodi
kda
antibodi
fragment
antigenbind
fragment
fab
kda
singlechain
variabl
fragment
scfv
kda
nb
monom
gener
exhibit
excel
solubl
strong
stabil
good
tissu
penetr
mainli
due
small
size
kda
case
increas
efficaci
viral
infect
bispecif
multispecif
multival
nb
construct
tandemli
link
two
nb
monom
recogn
either
differ
epitop
contrast
mab
fragment
might
exhibit
reduc
express
stabil
affin
engin
recombin
engin
nb
exhibit
elev
antigenbind
affin
thu
extend
time
period
nb
bound
target
maintain
benefici
characterist
without
neg
affect
product
yield
solubl
stabil
take
advantag
properti
nb
especi
abil
form
function
bi
multispecif
nb
elev
activ
construct
two
merscov
rbdtarget
oligomer
nb
dinb
trinb
base
previous
develop
mononb
goal
identifi
antimerscov
nb
improv
bind
abil
superior
inhibit
broadspectrum
neutral
activ
merscov
infect
without
neg
affect
express
level
stabil
dinb
trinb
molecular
weight
kda
doubl
tripl
size
mononb
kda
respect
expect
engin
rbdspecif
mononb
impact
antibodi
express
mononb
dinb
trinb
could
express
high
level
yeast
cell
express
system
purifi
high
puriti
retain
conform
antigen
addit
larger
size
oligomer
nb
affect
stabil
like
mononb
oligomer
dinb
trinb
maintain
stabil
extrem
condit
test
includ
acid
alkalin
ph
proteas
pepsin
chaotrop
denatur
urea
high
temperatur
contrast
proteas
chemic
thermal
stabil
mer
mab
significantli
decreas
treatment
thu
unlik
mab
control
engin
merscov
rbdspecif
nb
develop
studi
maintain
key
characterist
nb
includ
intrins
stabil
high
express
intact
conform
nb
stabl
extrem
condit
transport
store
without
need
refriger
special
care
mark
advantag
rel
tradit
antibodi
significantli
simplifi
transport
therapeut
process
antibodi
particularli
middl
eastern
countri
gener
inadequ
transport
servic
high
temperatur
summer
merscov
rbdspecif
dimer
trimer
nb
develop
studi
also
sever
import
featur
relat
interfer
three
critic
step
merscov
infect
first
exhibit
significantli
greater
abil
mononb
bind
merscov
rbd
protein
without
rbd
mutat
diverg
merscov
strain
isol
differ
year
host
facilit
interact
increas
time
nb
bound
merscov
previous
demonstr
mononb
recogn
epitop
residu
around
merscov
rbd
second
rel
mononb
engin
oligomer
nb
strongli
block
rbd
bind
merscov
receptor
involv
key
step
viral
entri
infect
therebi
effect
block
entri
merscov
target
cell
third
dinb
trinb
significantli
greater
capac
neutral
homolog
merscov
strain
well
potent
crossneutr
dozen
heterolog
merscov
strain
harbor
one
two
mutat
rbd
isol
differ
countri
host
human
camel
time
period
overal
engin
oligomer
nb
great
potenti
neutral
new
merscov
strain
mutat
rbd
could
therefor
play
key
role
prevent
cameltohuman
humantohuman
transmiss
merscov
despit
signific
advantag
nb
note
engin
dimer
kda
trimer
kda
nb
well
monomer
counterpart
kda
smaller
igg
antibodi
kda
molecular
weight
far
kidney
filtrat
threshold
kda
therefor
small
nb
may
rapidli
elimin
bloodstream
renal
clearanc
thu
might
shorter
halfliv
mab
one
approach
increas
vivo
halflif
nb
fuse
albuminbind
domain
abd
human
fc
hfc
also
success
fuse
monomer
nb
ctermin
hfc
increas
halflif
well
therapeut
prophylact
efficaci
merscov
infect
futur
studi
plan
extend
halfliv
construct
oligomer
nb
fuse
abd
hfc
compar
vivo
efficaci
mononb
without
hfc
merscov
summar
studi
develop
oligomer
merscov
rbdspecif
nb
demonstr
vitro
activ
superior
monomer
nb
counterpart
includ
antigenbind
affin
inhibit
bind
enhanc
neutral
crossneutr
activ
variant
strain
merscov
infect
without
reduc
stabil
harsh
condit
nb
potenti
develop
therapeut
prevent
treat
merscov
infect
similar
strategi
could
appli
develop
therapeut
agent
emerg
reemerg
infecti
virus
pandem
potenti
